AAAAAA

   
Results: 1-7 |
Results: 7
THE IMPORTANCE OF BIOLOGICAL FACTORS (BCL-2, BAX, P53, PCNA, MTI, HPVAND ANGIOGENESIS) IN INVASIVE CERVICAL-CANCER
Authors: TJALMA W WEYLER J BOGERS J BAAY M VERMORKEN J BUYTAERT P VANMARCK E VANDAM P
Citation: W. Tjalma et al., THE IMPORTANCE OF BIOLOGICAL FACTORS (BCL-2, BAX, P53, PCNA, MTI, HPVAND ANGIOGENESIS) IN INVASIVE CERVICAL-CANCER, Annals of oncology, 9, 1998, pp. 313-313
PHASE-I CLINICAL AND PHARMACOKINETIC (PK) STUDY OF ECTEINASCIDIN-743 (ET-743) GIVEN AS A ONE-HOUR INFUSION EVERY 21 DAYS
Authors: BOWMAN A TWELVES C HOEKMAN K SIMPSON A SMYTH J VERMORKEN J HOPPENER F BEIJNEN J VEGA E JIMENO J HANAUSKE AR
Citation: A. Bowman et al., PHASE-I CLINICAL AND PHARMACOKINETIC (PK) STUDY OF ECTEINASCIDIN-743 (ET-743) GIVEN AS A ONE-HOUR INFUSION EVERY 21 DAYS, Annals of oncology, 9, 1998, pp. 452-452
PHASE-I AND PHARMACOKINETIC STUDY OF ECTEINASCIDIN-743 (ET-743) GIVENAS A ONE-HOUR INFUSION EVERY 21 DAYS
Authors: TWELVES CJ VERMORKEN J BOWMAN A SIMPSON A SMYTH J HOPPENER F BEIJNEN J JIMENO J HANAUSKE AR
Citation: Cj. Twelves et al., PHASE-I AND PHARMACOKINETIC STUDY OF ECTEINASCIDIN-743 (ET-743) GIVENAS A ONE-HOUR INFUSION EVERY 21 DAYS, European journal of cancer, 33, 1997, pp. 1107-1107
HUMORAL IMMUNE-RESPONSE TO POLYMORPHIC EPITHELIAL MUCIN (MUC-1) IN PATIENTS WITH BENIGN AND MALIGNANT BREAST-TUMORS
Authors: VONMENSDORFFPOUILLY S GOUREVITCH MM KENEMANS P VERSTRAETEN AA LITVINOV SV VANKAMP GJ MEIJER S VERMORKEN J HILGERS J
Citation: S. Vonmensdorffpouilly et al., HUMORAL IMMUNE-RESPONSE TO POLYMORPHIC EPITHELIAL MUCIN (MUC-1) IN PATIENTS WITH BENIGN AND MALIGNANT BREAST-TUMORS, European journal of cancer, 32A(8), 1996, pp. 1325-1331
GEMCITABINE IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA OR GASTRIC-CANCER - PHASE-II STUDIES OF THE EORTC EARLY CLINICAL-TRIALS GROUP
Authors: SESSA C AAMDAL S WOLFF I EPPELBAUM R SMYTH JF SULKES A HUININK WTB VERMORKEN J WANDERS J FRANKLIN H VERWEIJ J
Citation: C. Sessa et al., GEMCITABINE IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA OR GASTRIC-CANCER - PHASE-II STUDIES OF THE EORTC EARLY CLINICAL-TRIALS GROUP, Annals of oncology, 5(5), 1994, pp. 471-472
PRELIMINARY-RESULTS OF 2 DOSE-FINDING STUDIES OF PACLITAXEL (TAXOL) AND CARBOPLATIN IN NONSMALL CELL LUNG AND OVARIAN CANCERS - A EUROPEAN-CANCER-CENTER EFFORT
Authors: GIACCONE G HUIZING M HUININK WT KOOLEN M POSTMUS P VANKRALINGEN K VANZANDWIJK N VERMORKEN J BEIJNEN J DALESIO O PINEDO H VEENHOF C
Citation: G. Giaccone et al., PRELIMINARY-RESULTS OF 2 DOSE-FINDING STUDIES OF PACLITAXEL (TAXOL) AND CARBOPLATIN IN NONSMALL CELL LUNG AND OVARIAN CANCERS - A EUROPEAN-CANCER-CENTER EFFORT, Seminars in oncology, 21(5), 1994, pp. 34-38
CA-125 HALF-LIFE IN OVARIAN-CANCER - A MULTIVARIATE SURVIVAL ANALYSIS
Authors: YEDEMA CA KENEMANS P VOORHORST F BON G SCHIJF C BEEX L VERSTRAETEN A HILGERS J VERMORKEN J
Citation: Ca. Yedema et al., CA-125 HALF-LIFE IN OVARIAN-CANCER - A MULTIVARIATE SURVIVAL ANALYSIS, British Journal of Cancer, 67(6), 1993, pp. 1361-1367
Risultati: 1-7 |